Patients with colorectal cancer and livermetastases planned for hemihepatectomy following portal embolisation
Conditions
Interventions
Trade Name: Erbitux 5mg/ml
Pharmaceutical Form: Solution for infusion
Sponsors
Karolinska University Hospital, Huddinge
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Liver met of CRC Planned for hemihepatectomy following portal embolisation of the ipsilateral liver lobe and expansion of the contralateral liver lobe. Medically fit for hemihepatectomy Responder to downsizing combination chemotherapy Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Extrahepatic CRC lesions Known allergy to cetuximab Previous exposure to cetuximab
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: prevention of growth of liver metastase during liver expansion;Secondary Objective: prevention of new liver metastases evaluation of expansion of healthy liver volume survival ;Primary end point(s): Total sum of liver metastases diameter for each patient measured by CT as baseline at start of cetuximab and evaluated by CT 6 weeks after portal embolisation. The follow-up CT will be evaluated for changes in the total sum of lesion diameters and expansion of the contralateral liver volume. occurence of new lesions will be registered. | — |
Countries
Sweden
Outcome results
None listed